Company news
Simcere Pharmaceutical Group Limited (HKEX:2096) news
Every Simcere Pharmaceutical Group Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
September 1, 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
November 10, 2025
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refr...
June 18, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 16, 2025
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
June 26, 2024
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
December 20, 2022
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
September 28, 2022
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 6...
September 5, 2022
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
February 23, 2022
Simcere Pharmaceutical : FURTHER ANNOUNCEMENT PROFIT FORECAST IN RELATION TO DISPOSAL OF SUBSIDIARIES
April 28, 2021
Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL ON CLINICAL TRIAL APPLICATION FOR THE ADDITION OF NEW INDICAT...
April 16, 2021
Simcere Pharmaceutical : CHANGE IN USE OF PROCEEDS
April 15, 2021
Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE CLINICAL TRIAL APPROVAL FOR SIM-307 ISSUED BY THE CENTER FOR DRUG EVAL...
April 13, 2021
Simcere Pharmaceutical : RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER
March 31, 2021
Simcere Pharmaceutical : Revised Terms of Reference of the Strategy Committee
March 25, 2021
Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL OF PHASE III CLINICAL TRIAL APPLICATION FOR ADDITION OF NEW I...
March 21, 2021